Endocrine Abstracts May 2014 Volume 35 ISSN 1479-6848 (online) 16th European Congress of Endocrinology 2014 3 –7 May 2014, Wrocław, Poland published by bioscientifica Online version available at www.endocrine-abstracts.org Volume 35 May 2014 Endocrine Abstracts 16th European Congress of Endocrinology 3–7 May 2014, Wrocław, Poland EDITORS The abstracts were marked by the Abstract Marking Panel selected by the Programme Organising Committee ECE 2014 Programme Organising Committee Paolo Beck-Peccoz Anna Spada Chair Chair Members Max Bielohuby Justo Castan˜o Niki Karavitaki Marta Korbonits Krzysztof Kula Agnes Linlart Sten Lund Valeriya Lyssenko Andrej Milewicz Efisio Puxeddu Hans Romjin Allan Vaag Peter Varnai M Donath Switzerland J Drouin Canada L Duntas Greece G Eisenhofer Germany S Farooqi UK M Felicia Italy A Ferlin Italy C Follin Sweden J Frystyk Denmark L Fugazzola Italy C Gaston UK A-P Gimenez-Roqueplo France E Gregoraszczu Poland S Hahner Germany N Hamdy Netherlands T Hansen Denmark TK Hansen Denmark B Hemmingsen A Hoeflich Germany L Hofbauer Germany P-M Holterhus Germany E S Husebye Norway A Januszewic Poland N Jessen Denmark D Jezova A Juul Denmark G Kahaly Germany F Karpe UK M Keil F Kelestimur Turkey RD Kineman USA P King UK ST Knudsen Denmark M Korbonits UK K Kula Poland J Lenders Netherlands NR Leslie UK A Luger Austria RM Luque Spain M Luster Germany M Manelli Italy C Mathieu Belgium J Mittag Sweden J Newell-Price UK M Niedziela Poland S Nielsen Denmark E Nieschlag Germany P Nilsson Sweden S Pearce UK S Petersenn Germany JR Petrie UK M Pfeifer Sweden V Pirags Latvia A Pizzocaro Italy D Power Portugal PL Poulsen Denmark M Puig Spain S Radian UK M Robledo Spain C Ronchi Italy M Rossini Italy D Salvatore Italy L Sa¨vendahl Sweden N Skakkebaek Denmark J Smit Netherlands R Sustarsic N Taylor UK J Toppari Finland M Toth Z Toth M Tzanela Greece AJ Van der Lely Netherlands J van Eck Netherlands V Volke Estonia J L Wemeau France I Wilkinson UK Z Wu Germany P Yeoh UK J Young France L Zabuilene MC Zatelli Italy C Zillikens Netherlands Abstract Marking Panel A Agha Ireland M Albiero M Alevizaki Greece MS Andersen Denmark F Antoni A Beckers Belgium I Bernabeu Spain J Bertherat France F Beuschlein Germany M Bidlingmaier Germany M Blomberg-Jensen Netherlands J Bollerslev Norway C Bousquet France T Brue France C Buchanan UK F Cardona J Castano Spain P Chanson France M Charalambous UK B Chini Italy I Chiondini Italy L Chiovato Italy MS Cooper Australia L Czupryniak Poland C Daousi UK MT Dattani UK W De Herder Netherlands 16th European Congress of Endocrinology 2014, Wrocław, Poland SPONSORS The ESE would like to thank its Corporate Members and the ECE 2014 sponsors ECE Corporate Members Eli Lilly Ipsen Laboratoire HRA Pharma Merck Serono Novartis Pharmacueticals Novo Nordisk Pfizer Sandoz International Gmbh ViroPharma SPRL Gold Sponsors Ipsen Novartis Bronze Sponsors Alexion ESE Office Euro House 22 Apex Court Woodlands Bradley Stoke Bristol BS32 4JT, UK ECE 2014 Secretariat Bioscientifica Ltd Euro House, 22 Apex Court Woodlands Bradley Stoke Bristol BS32 4JT, UK Endocrine Abstracts (2014) Vol 35 Contact: Tel: Fax: E-mail: Web site: Contact: Tel: Fax: E-mail: Website: Andrea Davis +44 (0)1454 642247 +44 (0)1454 642222 [email protected] www.ese-hormones.org Claire Arrigoni +44 (0)1454 642240 +44 (0)1454 642222 [email protected] http://www.bioscientifica.com 16th European Congress of Endocrinology 2014, Wrocław, Poland CONTENTS 16th European Congress of Endocrinology 2014 PRIZE LECTURES AND BIOGRAPHICAL NOTES The European Journal of Endocrinology Prize Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . EJE1 The Geoffrey Harris Prize Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . GH1 PLENARY LECTURES Genes, environment and endocrine disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Advances in molecular pathogenesis of thyroid cancer – therapeutic implications . . . . . . . . . Good times, bad times: (patho)physiology of diurnal rhythms . . . . . . . . . . . . . . . . . . . . Islet transplantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Simultaneous treatment of menopausal symptoms and prevention of breast cancer: Is it possible? Hypothalamic inflammation - cause or consequence of obesity? . . . . . . . . . . . . . . . . . . . Reproduction and energy metabolism, an ancestral balance to be preserved for women’s health . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . PL1 PL2 PL3 PL4 PL5 PL6 PL7 Endocrine changes and treatment needs in critically ill patients . . . . . . . . . . . . . . . . . . . . Pituitary development – from basic research to clinical practice . . . . . . . . . . . . . . . . . . . . News from thyroid hormones: central transport, energy control and oxidative stress . . . . . . . . Endocrine Nurses Session 1: Craniopharyngioma . . . . . . . . . . . . . . . . . . . . . . . . . . . . Obesity Beyond BMI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Focus on novel developments of PCOS - conclusions from the PCOS Task Force . . . . . . . . . . . Nontumorous pituitary diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Membrane lipid composition and receptor function. Signalling and trafficking . . . . . . . . . . . . EYES Session - Cold metabolic inflammation in obesity: ignored complication and treatment target? Difficulties in the treatment of Graves’ orbitopathy . . . . . . . . . . . . . . . . . . . . . . . . . . . Long term outcome of ‘cured’ pituitary patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . Gut microbiota in diabetes and obesity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Endocrine Nurse Session 3: Meet the Nurse Expert - Management of Endocrine Emergencies . . . . Clinical outcome of medical intervention in Disorder of Sex Development (DSD) . . . . . . . . . . . Thromboembolism and contraception . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Metformin: old dog, new tricks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Cushing’s syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Endocrine disease during pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Osteoporosis - An update . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . New hormones and endocrine tissues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Dilemmas in hormonal replacements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Novel therapies for thyroid cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Neuroendocrine tumours . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Nutrient regulation of metabolism and endocrine systems . . . . . . . . . . . . . . . . . . . . . . . Gonadal hormones and obesity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Pitfalls in hormone measurement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Brown Adipose Tissue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Molecular pathophysiology for clinicians: receptor-related disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S1.1– S1.3 . S2.1– S2.3 . S3.1– S3.3 . S4.1– S4.3 . S5.1– S5.3 . S6.1– S6.3 . S7.1– S7.3 . S8.1– S8.3 . S9.1– S9.3 S10.1– S10.3 S11.1– S11.3 S12.1– S12.3 S13.1– S13.3 S14.1– S14.3 S15.1– S15.3 S16.1– S16.3 S17.1– S17.3 S18.1– S18.3 S19.1– S19.3 S20.1– S20.3 S21.1– S21.3 S22.1– S22.3 S23.1– S23.3 S24.1– S24.3 S25.1– S25.3 S26.1– S26.3 S27.1– S27.3 S28.1– S28.3 SYMPOSIA Endocrine Abstracts (2014) Vol 35 16th European Congress of Endocrinology 2014, Wrocław, Poland MEET THE EXPERT SESSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . MTE1 –MTE17 ORAL COMMUNICATIONS Thyroid clinical . . . . . . . . . Adrenal Clinical . . . . . . . . . Neuroendocrinology & Signalling Diabetes and Obesity 1 . . . . . Adrenal & Thyroid . . . . . . . . Bone, Calcium & Vitamin D . . . IGF-1 and Thyroid Basic . . . . Pituitary Clinical . . . . . . . . . Reproduction . . . . . . . . . . . Endocrine Tumours . . . . . . . Diabetes and Obesity 2 . . . . . Pituitary Basic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . OC1.1– OC1.5 . . OC2.1– OC2.5 . . OC3.1– OC3.5 . . OC4.1– OC4.5 . . OC5.1– OC5.5 . . OC6.1– OC6.5 . . OC7.1 OC7.5 . . OC8.1– OC8.5 . . OC9.1– OC9.5 OC10.1 – OC10.5 OC11.1 – OC11.5 OC12.1 – OC12.5 NURSE POSTERS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . N1–N8 POSTER PRESENTATIONS Adrenal cortex . . . . . . . . . . . . . . . . . . . . Adrenal Medulla . . . . . . . . . . . . . . . . . . . Bone and Osteoporosis . . . . . . . . . . . . . . . Calcium and Vitamin D metabolism . . . . . . . . Cardiovascular Endocrinology & Lipid Metabolism Clinical case reports – Pituitary / Adrenal . . . . Clinical case reports – Thyroid / Others . . . . . . Developmental Endocrinology . . . . . . . . . . . Diabetes (epidemiology, pathophysiology) . . . . . Diabetes complications . . . . . . . . . . . . . . . Diabetes therapy . . . . . . . . . . . . . . . . . . . Endocrine disruptors . . . . . . . . . . . . . . . . . Endocrine tumours and neoplasia . . . . . . . . . Female reproduction . . . . . . . . . . . . . . . . . Growth hormone IGF axis – basic . . . . . . . . . Male reproduction . . . . . . . . . . . . . . . . . . Neuroendocrinology . . . . . . . . . . . . . . . . . Nuclear receptors and signal transduction . . . . . Obesity . . . . . . . . . . . . . . . . . . . . . . . . Paediatric endocrinology . . . . . . . . . . . . . . Pituitary – Basic (Generously supported by IPSEN) . Pituitary – Clinical (Generously supported by IPSEN) Steroid metabolism and action . . . . . . . . . . . Thyroid (non-cancer) . . . . . . . . . . . . . . . . Thyroid cancer . . . . . . . . . . . . . . . . . . . . INDEX OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P1– P56 . . . P57– P64 . . P65 – P100 . P101 – P168 . P169 – P209 . P210 – P260 . P261 – P332 . P333 – P339 . P340 – P402 . P403 – P461 . P462 – P501 . P502 – P513 . P514 – P613 . P614 – P667 . P668 – P683 . P684 – P708 . P709 – P735 . P736 – P739 . P740 – P792 . P793 – P825 . P826 – P836 . P837 – P945 . P946 – P957 . P958 –P1082 P1083 –P1152 16th European Congress of Endocrinology 2014, Wrocław, Poland Poster Presentations Endocrine Abstracts (2014) Vol 35 16th European Congress of Endocrinology 2014, Wrocław, Poland P1053 Thyroid volume in adult b-thalassemic patients is smaller than in controls Anna Ansaloni1,2, Chiara Diazzi1,2, Daniele Santi1,2, Giulia Brigante1,2, Francesca Ferrara3, Antonello Pietrangelo3 & Vincenzo Rochira1,2 1 Chair of Endocrinology and Metabolism, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy; 2Division of Endocrinology Integrated, Department of Medicine, Endocrinology and Metabolism, Geriatrics, Azienda USL of Modena, NOCSAE of Baggiovara, Modena, Italy; 3Division of Internal Medicine and Center for Hemochromatosis, ‘Mario Coppo’ Liver Research Center, University Hospital of Modena, Modena, Italy. Introduction Thyroid function is commonly impaired in b-thalassemic patients with an estimated prevalence of hypothyroidism of 9–11%. According to literature, iron overload is the main cause of tissue damage involving both thyroid and pituitary gland, thus leading to primary or secondary hypothyroidism respectively. However, thyroid morphology has been rarely investigated in adults. The aim of this study is to evaluate thyroid volume (TV) and thyroid morphology in b-thalassemic adult patients compared to healthy controls. Methods We performed a cross-sectional, controlled study in 13 b-thalassemic adult patients (six males and seven females) (36.36G4.26 years) and 120 healthy volunteers (28 males and, 92 females) (38.1G4.9 years). All subjects underwent thyroid ultrasonography performed by the same operator. TV was calculated as the sum of the volume of the two lobes, each estimated by standardized formula: length!width!depth!0.479. Ultrasound evaluation included the presence/ absence of hypoechogenicity and echotexture heterogeneity, and the presence/ absence of nodules. Results TV was significantly lower in b-thalassemic patients (5.41G1.33 ml) than in the control group (8.45G2.81 ml) (P!0.001) independently from their thyroid function (euthyroidism or hypothyroidism). The prevalence of diffuse echotexture heterogeneity and hypoechogenicity of the thyroid was significantly higher in thalassemic patients (92.3%) than in the control group (42.4%) (P!0.001). Thyroid antibodies were negative in all thalassemic patients. Thyroid nodules were found in four thalassemic patients (30.7%) and in 44 volunteers (36.7%) (PZ0.674). Discussion In adult b-thalassemic patients TV was smaller than in healthy subjects even when patients with a normal thyroid function were considered. Moreover the prevalence of hypoechogenicity and echotexture heterogeneity, without a confirmed diagnosis of autoimmune thyroiditis, was higher. These results suggest a primary thyroid damage, characterized by thyroid hypoplasia and tissue alterations probably caused by iron infiltrates. Furthermore, the risk of developing thyroid nodules seems not to be increased in beta-thalassemic patients. DOI: 10.1530/endoabs.35.P1053 P1054 Steroid treatment in patients with active moderate-to-severe Graves orbitopathy Theodora Tsirouki1, Zoi Giotaki3, Andreas Rizoulis2, Stelios Tigas3, Ioannis Asproudis4, Agathocles Tsatsoulis3, Eftychia Kapsalaki5, Evaggelia Tsironi1, Georgios N Koukoulis2 & Alexandra Bargiota2 1 Ophthalmology Clinic, University Hospital of Larisa, Larisa, Greece; 2 Endocrinology Clinic, University Hospital of Larisa, Larisa, Greece; 3 Endocrinology Clinic, University Hospital of Ioannina, Ioannina, Greece; 4 Ophthalmology Clinic, University Hospital of Ioannina, Ioannina, Greece; 5 Department of Diagnostic Radiology, University Hospital of Larisa, Larisa, Greece. Background Although IV steroids are the treatment of choice for moderate-to-severe graves orbitopathy (M-S GO), the most efficacious regimen is not yet defined. Cases not responding or relapsing after steroid treatment (STx) are not uncommon and STx can cause serious adverse events. The aim of the present study is to define the steroid regimen which balances between efficacy and damage, using stir-sequence orbital-MRI (SsMRIo) as an additional objective tool for the evaluation of activity and severity of GO. Endocrine Abstracts (2014) Vol 35 Methods Forty-seven patients with M-S GO received a cumulative dose of 4.5 g of methylprednisolone in 12 weekly doses. Two weeks post iv-STx, peros-STx (prednisolone for 3 months) was administered to patients with clinical and MRI findings of active disease. CAS and TES scores were measured at baseline, 6, 12 and 24 weeks and SsMRIo was performed at baseline and 12 weeks. Quality of life was evaluated (GO-QoL questionnaire) at baseline, 12 and 24 weeks. Results Age was 58.46G13.37 (meanGS.D.), 70.2% were females and 37.8% current smokers. Duration of ocular symptoms was 12.22G13.23 months. Owing to adverse events 10.6%(5/47) discontinued iv-STx. Peros-STX following the IV received 52.4% (22/42) based on the SsMRIo. At the end of the treatment significantly better CAS (CAS at baseline: 6.06G1.17 and at 24 weeks:1.28G 1.55, P!0.001) and TES scores (TES at baseline:18.33G6.63 and at 24 weeks: 8.68G7.24, P!0.001) were observed. QoL significantly improved in all domains (Social function at baseline: 3.77G2.79 and at 24 weeks: 7.45G2.98, PZ0.000, dependency at baseline: 5.45G3.21, at 24 weeks: 9.05G2.19, PZ0.000). Recurrence was comparable in the groups (2/22 and 2/20 patients after having and not having received peros-STx). Conclusions Combination of iv-STX and peros-STx is an efficacious and safe regimen for the treatment of GO. SsMRIo can improve the detection of those cases which remain active and need further peros-STx after the iv-STX. DOI: 10.1530/endoabs.35.P1054 P1055 The influence of radioiodine therapy in 1600 patients with subclinical hyperthyroidism Saeid Abdelrazek1, Piotr Szumowski1, Janusz Mysliewiec1, Maria Kosciuszko2, Malgorzata Szelachowska2 & Maria Gorska2 1 Department of Nuclear Medicine, Medical University of Bialystok, Bialystok, Poland; 2Department of Endocrinology Diabetolgy and Internal Medicine, Medical University of Bialystok, Bialystok, Poland. The aim of our study was to assess the influence of radioiodine (131I) therapy on the achievement of euthyroidism, prevention of adverse effects on the cardiovascular and prevent evolvement to overt hyperthyroidism. Materials and methods We treated 1600 patients refered to our department during the last 8 years, aged 23–77 years; 89% of them were females and 11% males; 520 patients with multinodular goitre (MNG), and 1080 patients with autonomous nodule (ATN). Some of the patients were treated with antithyroid drugs for 1–3 months before 131 I therapy (148 patients). Malignant changes were excluded in all nodules by fine-needle aspiration biopsy. All the patients had serum TSH levels !0.1 mU/l and effective T-half was more than 3 days at the time of treatment. The activity dose was calculated by the use of Marinelli’s formula and ranged between 200 and 800 MBq. The absorbed dose (Gy) ranged between 180 and 300, and was proportional to thyroid volume. Follow-up control was done every 6 weeks. Results Euthyroidism achieved in 99% of patient with ATN and 93% of MNG; 1% of patients with ATN and 6% of patients with MNG develop hypothyroidism. One percentage of patients with MNG were in subclinical hyperthyroidism and received second dose of radioiodine therapy. In all of the patients, the symptoms and signs of subclinical hyperthyroidism disappeared (palpitation, tachycardia, atrial fibrillation, exercise tolerance improved, the blood pressure normalised and the quality of life improved). Conclusions The achievement of euthyroidism and the remission of the symptoms and signs of subclinical hyperthyroidism, were due to good diagnosis, well preparation of the patients; accurate measurement of administered activity, effective half-life, and well-organised follow-up. We recommend early treatment of subclinical hyperthyroidism, and long period of follow-up to evaluate the long-term effect of radioiodine therapy. Subclinical hyperthyroidism, and long period of follow-up to evaluate the longterm effect of radioiodine therapy. DOI: 10.1530/endoabs.35.P1055 16th European Congress of Endocrinology 2014, Wrocław, Poland Author Index Abaci, N P593 Abarikwu, S P708 Abbara, A OC3.1, OC9.4 & P617 Abbaszadegan, MR P108 Abdallah, NB P840 Abdelrazek, S P1041 & P1055 Abdin, A P320 & P552 Abdollahi, M P405 Abdulla, H P848 Abeguile, G P148 Aberer, F P488 Aberle, J P581 Abeysinghe, P P786 Abi, A P472 Abouglila, K P846 Abrahamsson, N P770 Abraitiene, A P838 Abramavicius, S P369 Abreu, A P711 Abrosimov, AY P1108 Abs, R S21.3 Acar, B P343 Acar, FZ P1036 & P31 Acibucu, F P1120 Acikgoz, E P753 Ackermans, MT P946 Adamcova, M P22 Adamek, D P829 Adamidou, F P167 & P314 Adamska, A P134 & P663 Adamska, E OC4.1 & P776 Adas, G P14 Adas, M P14 Ademoglu, E P115 Adhiyaman, V P249 Adorini, L P696 Adukauskiene, D P931 Adversi, F P643 Ae Lee, K P1085 Aflorei, ED OC12.1 Afzal, N P1032 Agackiran, Y P136 Agapito, A P654 & P780 Agata, K P124 Agbaht, K P742 Aghaei, M P71 Aghajanova, Y P120 & P477 Aghili, R P405 Agnieszka, C OC5.5 Aguiar, A P631 Aguilar-Diosdado, M P206, P393, P395, P398 & P496 Ahmed, A P1089 Ahmeti, I P248 Ahn, KJ P342 & P429 Aigelsreiter, A P192 Aimaretti, G P145 AiMin, X P771 Ajduk, M P785 Akc¸ay, G P66 Akbal, E P968 Akbay, E P270 & P271 Akcay, T P821 Akgul, OF P244, P245 & P632 Akhtar, S P951 Akin, F OC9.5, P1027, P263, P264 & P380 Akin, S P48 & P917 Akkurt, A P531 Akopyan, S P120 Akpinar, G P1010 Akpinar, S P275 Aksana, K P805 Aksoy, A P115 Aksyonova, E P778 Aktimur, R P126 Akturk, M P1030, P151, P492 & P700 Akyildiz, M P171 & P172 Al-Dujaili, E P170 Al-Hayek, A P351 Al-Sabaan, F P351 Al-Saeed, A P351 Alacacioglu, A P332 Albarel, F P875 Alberiche, MdP P1073 Albersmeyer, M P868 Alborg, VC P909 Albrecht, E P739 Alebic, MS P686 Aled Rees, D OC5.2 Aleksandra, K OC5.5 Alesse, E P834 & P835 Alevizaki, M P1080 & P1102 Alexander Iwen, K OC7.5 Alexandraki, K P537, P598 & P608 Alexianu, M P815 Alexopoulou, O P860 Alfaro, JJ P467 Algu¨n, E P10 Alhumaidi, N P77 Ali Alhamza, AH P1 Ali Mansour, A P1 Ali, LA P542 Aliev, A P1050 & P584 Alikasifoglu, M P388 Alimova, N P358 & P417 Alkhalaf, F P77 Allelein, S P613 Allolio, B OC2.2, OC3.2, OC5.3, P2, P533 & P535 Almagro, RM P1002 & P1003 Almanza, MR P909 Almeida, R P823, P926 & P943 Almeida, T P654 Almomin, AMS P1 Alobedallah, A P351 Alonso, AA P575 Aloumanis, K P67 & P68 Alt-Tebacher, M P1042 Altas, A P1058 Altieri, B P535 Altinok, M P618 Altinova, A P446 & P492 Altinova, AE P1030 & P151 Altun, B P968 Altunbas, HA P131, P74 & P900 Altundal, N P894 Altunel, MS P432 & P433 Altunkaya, C P279 & P285 Altunoren, O P238 Altuntas, Y P221 & P472 Alves, M P1009, P327, P53, P546 & P547 Alves, MG P571 Alves, MR P702 Alves, R P461 Amani, MEA P984 & P985 Amar, L P49 Amaral, C P329, P457, P764 & P769 Amaral, D P807 Amaral, FG P719 Amaro, T P1149 Ambroziak, U P338 Ammini, A P335 Ammini, AC P580 & P582 Amrani-Raissouni, T P106 Amselem, S P675 Amzar, D P543, P573 & P893 Anaforog˘lu, P10, P23 & P729 Anagnostis, P P167 & P314 Anastasiu, D P65 Andersen, AS P337 Andersen, LLT P621 Andersen, M P618, P621 & P673 Andersen, MN OC1.2 Anderwald, C P129 Andrada, P P781 Andreas, B P714 Andreas, H P714 Andres, E P1042 Androulakis, I P641 Andrusiewicz, M P1119 & P836 Andrysiak-Mamos, E P100, P604 & P99 Andujar-Plata, P P731 Anelli, S P530 Angelini, F P937 Angelini, M S16.3 Angelopoulou, A P1102 Angelova, P P156 Anghel, GC P733 Anghel, R P734 Anheˆ, GF P719 Anil, C P403 & P468 Anna, S P180 Ansaloni, A P1053 & P924 Ansari, NE P72 Antic, IB P299, P313, P623, P624 & P625 Antic, S P828 Antiguedad, CG P445 Anton, M P814 Antonelou, M P920 Antosz, A P587 Antunes, A P823 Anwer, U P685 & P699 Aout, M P885 & P907 Apaydin, MA P863 Apollonatou, S P950 Apolloni, G P957 Apostolakis, M P1102 Arıkan, P958 Arau´jo-Vilar, D P811 Arabaci, E OC1.1 Aragu¨e´s, JM P350 Arakelyan, L P120 Aral, F P593 Aral, Y P385 16th European Congress of Endocrinology 2014, Wrocław, Poland Regadera, J P738 Reghina, AD P431 Reimondo, G P8 Reincke, M MTE5, OC2.2, OC5.4, P203, P37, P564, P568 & P7 Reisch, N S14.1 Renata, C P1103 Rentziou, G P1102 Requena, JR P811 Requena, M P237 & P445 Rese´ndiz, KH P918 Resch, J OC7.5 Resmini, E OC12.5 Ress, C P861 Reyes-Garcı´a, R P91 Rezvani, R P773 Rheinheimer, J P365 Ribalta, MT P722 Ribeiro, C P1111 Riesco-Eizaguirre, G PL2 Ricciuti, A OC12.3 Richard, N P148 Richter-Unruh, A S14.1 Ricotti, R P145 & P27 Ridruejo, E P687 Ries, M P2 Rieske, P P97 & P98 Riester, A P37 & P568 Rigas, G P748 Rimpau, J P735 Rinaldi, E P47 Rinco´n-Ferna´ndez, D P516 Rindi, G P549, P551 & P578 Ripoll, RQ P909 Risbridger, G OC10.4 Ritvonen, E P881 Ritzel, K P7 Rivadeneira, L P237 & P445 Rivera, NG P51 & P597 Rivera, R P741 Rivero-Corte´s, E OC12.2 Rivory, P P652 Rizoulis, A P1054 Rizvi, S P1031 Rizvi, SSR P1032, P685 & P699 Roa, R P487 Roberts, J P914 Robledo, M P1095 Roca, M P500 Roca-Rodrı´guez, M P261 Roccio, M P27 Rochira, V P1053, P519, P701, P924 & P955 Rodrı´guez Gutie´rrez, FJ P1003 Rodrı´guez, C P1073 Rodrı´guez, E P1073 Rodrı´guez, JP P51 & P597 Rodrı´guez, R P322 Rodrı´guez-Medina, B P695 Rodrı´guez-Molina, JM P186 Rodrigues, D P1009, P296, P325 & P327 Rodrigues, E P889 Rodrigues, P P17 Rodrigues, SC P719 Rodriguez, JP P498 Roemmler-Zehrer, J P735 Rogin´ska, D P54 Rogowicz-Frontczak, A P378 & P420 Roine, R P881 Rojo-Martinez, G P789 Roma´n, MM P376 Romanelli, MMC P766 Romero, AO P743 Romero, MF P743 Romualdi, D P653 Ronchi, C OC2.3 & P533 Ronchi, CL OC2.2, OC5.3 & P535 Rosłonowska, E P557 Rosado, V P1095 Rosc, D P408 Rosca, R P204 Rosca, RI P529 Rosell, J P515 Rosenwald, A OC5.3 Roskosz, J OC1.5 & P1098 Roslon, M P1139 Ross, I P40 Ross, R P30 & P825 Ross, RJ OC5.2 Rossetti, P P1007 Rossetti, R P646 Rossi, M P692, P694 & P704 Rossi, S P1126 Rostomyan, L P834 Roszak, M P1021 Rotermund, R P581 Rothenbuhler, A P140 Rotondi, S P834 & P835 Rousso, D P1047 Roux, A P652 Rozhinskaya, L P119, P24, P730, P912, P919 & P934 Rozhko, A P181 Rozkowszka, K P557 Ruas, L P1008, P1009, P1111 & P296 Rubin, B P12 & P536 Rubino, M P128 Ruby, LCH P771 Ruchała, M P1035, P1044, P1119, P202, P338, P36, P836, P982 & P983 Ruchala, M P326, P563, P996 & S10.2 Rudnicka, M P99 Rudnik, A P832 Rudzinska, M P1131 & P1135 Rudzki, G P254, P258 & P556 Ruiz-Riquelme, A P811 Rupa, R P849 Ruprecht, Z P408 Rusak, M P776 & P818 Rusakov, V P266, P267 & P268 Rusalenko, M P181 Rusinek, D OC3.5 & P1152 Rusu, C P795, P814 & P819 Ruszkowska-Ciastek, B P408 Ruszniewski, P P577 & P578 Rutishauser, J OC3.2 & P18 Rutkowska, A P511 Rutkowska, B P952 Rutter, M OC11.2 Ruvo, MD P831 Rybalchenko, V P422 Rybka, J P372 Rybka, W P372 Rydzanicz, M P338 Rymaszewska, J P127 & P930 Rys, A P157, P309 & P777 Ryu, OH P384 Ryzhenkova, MI P1108 Sa´, J P389 & P390 Sa´daba, MC P669 Sa´nchez, A P1073 Sa´nchez, F P205 Sa´nchez, JRC P575 Sa´nchez, R P1073 Sa´nchez-Garcı´a, F P515 Sa´nchez-Iglesias, S P811 Sa´nchez-Zambrano, M P205 Sa´sikova´, M P884 Se˛siadek, M P890 Słapa, R P557 Słoka, N P127 Słowin´ska-Srzednicka, J P557 Sørensen, H P673 Sørensen, JA P621 Saad, F P478, P696, P754 & P755 Saaid, N P107 Saavedra, A P936 Sabino, T P654 & P780 Sabir, I P335 Sabt, A P77 Sacchi, S P639 Sacikara, M P136, P305, P635, P980 & P987 Sadikova, E P142 & P375 Sadowski, T P160 Sadurska, E P1004 Sadykova, A P417 & P418 Saeger, W P901 Safari, R P71 Sag, S P753 Sagala, M P806 Saglam, F P1065, P305, P421, P78 & P981 Sagliker, HS P231 & P301 Sahin, D P442 Sahin, F P69 Sahin, H P244 & P295 Sahin, I P1048 & P490 Sahin, M OC8.3, P139, P146, P183, P228, P230, P231, P238, P244, P245, P295, P301, P437, P5, P632, P638 & P994 Saini, S P746 Saito, H P76 Sajardo, RB P575 Sajevets, T P277 Sajid, W P337 Sak, SD P61 Sakamoto, M P232 & P897 Sakamoto, N P232 Saklamaz, A P171 & P172 Sala, E P845 & P898 Sala, GBL P643 Salam, R P107 & P959 Salas, MS P237 & P445 Salas-Salvado´, J S29.1 Salcuni, AS P81 Salgado, C P1149
© Copyright 2024 Paperzz
